|
Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in pulmonary delivery of systemic drug therapies is focused on chronic diseases and refractory conditions - aliments that require frequent drug administration for a protracted period of time.
The role of device design and development in defining and driving emerging opportunities in this sector cannot be overstated. Nebulizers, metered dose inhalers (MDIs), and dry powder inhalers (DPIs) have each found a niche in the quest for optimal treatment and convenient use. While nebulizers have evolved relatively independently of the drug formulations they deliver, the current generation of MDIs and DPIs have been developed or tailored for the specific pharmaceutical being delivered, resulting in improved performance.
Several of the emerging drug products covered in this report will have a significant impact in the therapeutic markets they target, improving patient compliance and effectively changing the way important illnesses and conditions are treated.
Feature Summary- Analyzes and evaluates inhaled drugs currently in development and assesses the market potential for existing and probable future products- Examines inhalation device technology for commercial and development-stage devices, and evaluates product technology issues and evolving market factors- Provides detailed assessments of targeted disease segments, forecast growth and market potential, and therapeutic options- Forecasts the impact of new and emerging inhaled drug therapeutics on healthcare markets and prescribing decisions to 2012- Profiles Inhaled drug product market participants, their technology, product development activity, and business strategies- Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners
Methodology- Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.- Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.- Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.
Executive Summary
Inhaled Drug Delivery Market Dynamics - Established Therapeutic Targets - Emerging Therapies - Demographics and Growth - Competing Technologies - Market Drivers - Factors Limiting Growth
Inhalation Technology & Product Development Factors - Drug Formulations - Formulation Technologies - Delivery Profiles and Risk Factors - Excipients and Release Profiles - Inhalation Device Design Factors - Dry Powder Inhalers - Metered Dose Inhalers - Nebulizers - Performance Factors - Bioavailability - Dose Reproducibility - Active Compound Stability - Combination Drug Inhalers - Testing and Packaging - Emerging Device Technologies
Inhalation Devices - Device Assessments and Product Strategies - Dry Powder inhalers - Commercial Devices - Discrete Dose Devices - Reservoir Devices - Proprietary Dosing Technologies - Development-stage DPI Devices - Market Data and Forecasts - Metered Dose Inhalers - Commercial Devices - Pressurized MDIs - Breath-actuated MDIs - Advanced Design MDIs - Recent Technology Developments - Market Data and Forecasts - Nebulizers - Commercial Devices - Compressed Air Nebulizers - Ultrasonic Nebulizers - Advanced Technology Nebulizers - Recent Developments - Market Data and Forecasts
Inhaled Drug Delivery - Evolving Therapies, Products and Players - Upper Respiratory Indications - Asthma - Therapeutic Segment Analysis - Competitive Landscape - Prescribing Trends and Growth Factors - Emerging Inhaled Therapies - COPD - Therapeutic Segment Analysis - Competitive Landscape - Prescribing Trends and Growth Factors - Emerging Inhaled Therapies - Systemic Drug Delivery - Alpha-1 Deficiency - Aerosolized AAT - Bioterror - Atropine - Ciprofloxacin - Cystic Fibrosis - Arikace - Aztreonam - Bronchitol - Ciprofloxacin - Denufosol - Heparin - Lancovutide - Levofloxacin - Tobramycin - Zysolin - Diabetes - Afresa - Endocrinology - hGH - Immune System Modulators - Cyclosporine - Infectious Diseases - Amikacin - Interferon-? - ALN-RSV01 - Vancomycin - Influenza - CS-8958 - Laninamivir - PUR003 - Zanamivir - Neurology - Insomnia - Zelaplon - Migraine - Dihydroergotamine - Loxapine - Prochlorperazine - Triptan Analog - Parkinson's Disease - Apomorphine - Schizophrenia - Loxapine - Pulmonary Hypertension - Aironite - Ventavis/Iloprost - Treprostinil - Oncology - Cisplatin - Pain Management - Morphine - Fentanyl Product 1 - Fentanyl Product 2 - Fentanyl Product 3 - Sexual Health - Female Sexual Dysfunction - Apomorphine - Erectile Dysfunction - Apomorphine
Market Factors - Usability and Patient Preferences - Regulatory Issues - Patient Compliance - The Role of CMOs/CSOs
Company Profiles
|
